Why Precision Alone Isn't Enough in Oncology Drug Discovery
Precision alone isn’t enough in oncology drug discovery. See why execution, biomarkers, and trial design determine scalable success in precision medicine.
Phenotypic drug discovery is reshaping how pharma finds first-in-class drugs. This analysis covers the methods, AI integration, and strategic decisions R&D leaders face in 2026.
FDA 2026 Draft Guidance on Alternatives to Animal Testing
The FDA's March 2026 draft guidance on alternatives to animal testing marks a pivotal shift in preclinical drug development. Here's what pharma R&D teams need to know.
Optimising Preclinical Pharmacology for Oncology NMEs
Over 90% of oncology NMEs that succeed in animal studies fail in clinical trials. This analysis examines how to optimise preclinical pharmacology models to improve translational success.
